{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:02:10Z","timestamp":1789790530049,"version":"4.0.1"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T00:00:00Z","timestamp":1233619200000},"content-version":"vor","delay-in-days":4296,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[1997,5]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>The non\u2010hydrolysable cyclic AMP analogue, dibutyryl (Bu<jats:sub>2<\/jats:sub>)\u2010cyclic AMP, inhibited the stimulated release of histamine from both basophils and human lung mast cells (HLMC) in a dose\u2010dependent manner. The concentrations required to inhibit histamine release by 50% (IC<jats:sub>50<\/jats:sub>) were 0.8 and 0.7 m<jats:sc>M<\/jats:sc> in basophils and HLMC, respectively. The cyclic GMP analogue, Bu<jats:sub>2<\/jats:sub>\u2010cyclic GMP, was ineffective as an inhibitor of histamine release in basophils and HLMC.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The non\u2010selective phosphodiesterase (PDE) inhibitors, theophylline and isobutyl\u2010methylxanthine (IBMX) inhibited the IgE\u2010mediated release of histamine from both human basophils and HLMC in a dose\u2010dependent fashion. IBMX and theophylline were more potent inhibitors in basophils than HLMC. IC<jats:sub>50<\/jats:sub> values for the inhibition of histamine release were, 0.05 and 0.2 m<jats:sc>M<\/jats:sc> for IBMX and theophylline, respectively, in basophils and 0.25 and 1.2 m<jats:sc>M<\/jats:sc> for IBMX and theophylline in HLMC.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The PDE 4 inhibitor, rolipram, attenuated the release of both histamine and the generation of sulphopeptidoleukotrienes (sLT) from activated basophils at sub\u2010micromolar concentrations but was ineffective at inhibiting the release of histamine and the generation of both sLT and prostaglandin D<jats:sub>2<\/jats:sub> (PGD<jats:sub>2<\/jats:sub>) in HLMC. Additional PDE 4 inhibitors, denbufylline, Ro 20\u20131724, RP 73401 and nitraquazone, were all found to be effective inhibitors of mediator release in basophils but were ineffective in HLMC unless high concentrations (1 m<jats:sc>M<\/jats:sc>) were employed.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Neither 8\u2010methoxymethyl IBMX (PDE 1 inhibitor), zaprinast (PDE 5 inhibitor) nor a range of PDE 3 inhibitors (siguazodan, SKF 94120, SKF 95654) were effective inhibitors of mediator release from either basophils or HLMC.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In basophils, rolipram acted to potentiate the inhibitory effects of the adenylate cyclase activator, forskolin, whereas in HLMC, rolipram failed to potentiate the inhibitory effects of forskolin.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Extracts of purified HLMC and basophils hydrolysed cyclic AMP. IBMX (100 \u03bc<jats:sc>M<\/jats:sc>) inhibited the PDE activity in basophil extracts by 67\u00b17% (<jats:italic>P<\/jats:italic>&lt;0.0001) and in HLMC extracts by 63\u00b19% (<jats:italic>P<\/jats:italic>&lt;0.0005). The hydrolysis of cyclic AMP by basophil extracts was inhibited by the selective PDE inhibitors (all at 10 \u03bc<jats:sc>M<\/jats:sc>), rolipram (56\u00b18%, <jats:italic>P<\/jats:italic>&lt;0.0001) and the mixed PDE 3\/4 inhibitor, Org 30029 (47\u00b19%, <jats:italic>P<\/jats:italic>&lt;0.01), whereas 8\u2010methoxymethyl IBMX, siguazodan and zaprinast were ineffective. In HLMC, rolipram, Org 30029, 8\u2010methoxymethyl IBMX, siguazodan and zaprinast all inhibited the hydrolysis of cyclic AMP by extracts to a significant (<jats:italic>P<\/jats:italic>&lt;0.05) and similar extent (approximately 25% inhibition at 10 \u03bc<jats:sc>M<\/jats:sc>).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In total, these data suggest that modulation of the PDE 4 isoform can regulate basophil responses whereas an association of the PDE 4 isoform with the regulation of HLMC function remains uncertain.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (1997) <jats:bold>121<\/jats:bold>, 287\u2013295; doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0701115\">10.1038\/sj.bjp.0701115<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0701115","type":"journal-article","created":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T17:09:36Z","timestamp":1156525776000},"page":"287-295","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function"],"prefix":"10.1111","volume":"121","author":[{"given":"Marie C","family":"Weston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T","family":"Peachell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,2,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01983121"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb15120.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.95.08030457"},{"key":"e_1_2_6_5_1","first-page":"674","article-title":"The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity","volume":"273","author":"Barnette M.S.","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_6_1","first-page":"399","article-title":"Multiple cyclic nucleotide phosphodiesterases","volume":"46","author":"Beavo J.A.","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(90)90066-H"},{"key":"e_1_2_6_8_1","first-page":"44","article-title":"Differential inhibitor effects on cyclic adenosine monophosphate\u2010phosphodiesterase isoforms in atopic and normal leukocytes","volume":"121","author":"Chan S.C.","year":"1993","journal-title":"J. Lab. Clin. Med."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1991.tb09790.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-75840-9_4"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.4049\/jimmunol.153.8.3408","article-title":"Modulation of antigen\u2010 and mitogen\u2010induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors","volume":"153","author":"Essayan D.M.","year":"1994","journal-title":"J. Immunol."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1981.tb08748.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.9.3686"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.279.279"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb13278.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(95)90129-9"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.161.3844.902"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(91)90484-A"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1006\/pulp.1994.1001"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80186-1"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4049\/jimmunol.140.2.571","article-title":"Regulation of human basophil and lung mast cell function by cAMP","volume":"140","author":"Peachell P.T.","year":"1988","journal-title":"J. Immunol."},{"key":"e_1_2_6_22_1","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.148.8.2503","article-title":"Preliminary identification and role of phosphodiesterase isozymes in human basophils","volume":"148","author":"Peachell P.T.","year":"1992","journal-title":"J. Immunol."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(83)90345-0"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2410535"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(74)90093-1"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(91)90056-B"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15450.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb16317.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.46.7.512"},{"key":"e_1_2_6_30_1","first-page":"1195","article-title":"Stimulation of beta adrenoceptors in a human monocyte cell line (U937) upregulated cyclic AMP\u2010specific phosphodiesterase activity","volume":"263","author":"Torphy T.J.","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1993.tb13481.x"},{"key":"e_1_2_6_32_1","first-page":"209","article-title":"Isoproterenol\u2010induced inhibition of immunoglobulin E\u2010mediated release of histamine and arachidonic acid metabolites from the human lung mast cell","volume":"247","author":"Undem B.J.","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_33_1","first-page":"306","article-title":"Inhibition of antigen\u2010induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cAMP\u2010specific phosphodiesterae inhibitor, rolipram","volume":"266","author":"Underwood D.C.","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0701115","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0701115","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0701115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T05:35:49Z","timestamp":1698384949000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0701115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,5]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1997,5]]}},"alternative-id":["10.1038\/sj.bjp.0701115"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0701115","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,5]]},"assertion":[{"value":"2009-02-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}